Outlook Therapeutics Statistics
Share Statistics
Outlook Therapeutics has 32.62M
shares outstanding. The number of shares has increased by 39.37%
in one year.
| Shares Outstanding | 32.62M |
| Shares Change (YoY) | 39.37% |
| Shares Change (QoQ) | 30.98% |
| Owned by Institutions (%) | 17.72% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 24,880 |
| FTD / Avg. Volume | 6.05% |
Short Selling Information
The latest short interest is 4M, so 12.48% of the outstanding
shares have been sold short.
| Short Interest | 4M |
| Short % of Shares Out | 12.48% |
| Short % of Float | 16.54% |
| Short Ratio (days to cover) | 9.96 |
Valuation Ratios
The PE ratio is -1.31 and the forward
PE ratio is -1.85.
Outlook Therapeutics's PEG ratio is
-0.01.
| PE Ratio | -1.31 |
| Forward PE | -1.85 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | -1.44 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Outlook Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.64 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.42 |
| Debt / FCF | -0.43 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,276,813.65 |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.46% in the
last 52 weeks. The beta is 0.39, so Outlook Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -82.46% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 3.84 |
| Relative Strength Index (RSI) | 46.86 |
| Average Volume (20 Days) | 411,543 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.7M |
| Net Income | -75.37M |
| EBITDA | -71.59M |
| EBIT | -71.7M |
| Earnings Per Share (EPS) | -9.84 |
Full Income StatementBalance Sheet
The company has 14.93M in cash and 29.74M in
debt, giving a net cash position of -14.81M.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 29.74M |
| Net Cash | -14.81M |
| Retained Earnings | -543,284.9B |
| Total Assets | 17,006.1B |
| Working Capital | -32,569.9B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -68.79M
and capital expenditures 0, giving a free cash flow of -68.79M.
| Operating Cash Flow | -68.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -68.79M |
| FCF Per Share | -3.71 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
